参芪扶正注射液治疗非小细胞肺癌合并慢性阻塞性肺疾病的作用机制探讨  

Probe into the Mechanism of ShenQi FuZheng Injection in Treating Non-small Cell Lung Cancer with Chronic Obstructive Pulmonary Disease

作　　者：洪玮莉 梁琼 欧阳华[1] HONG Wei-li;LIANG Qiong;OUYANG Hua(Department of Pharmacy,Zhongshan Hospital Affiliated to Xiamen University,Xiamen 361004,China;Fujian Provincial Hospital,Fuzhou 350001,China)

机构地区：[1]厦门大学附属中山医院药学部,福建厦门361004 [2]福州大学附属省立医院,福建福州350001

出　　处：《海峡药学》2025年第2期1-7,共7页Strait Pharmaceutical Journal

基　　金：厦门市科协重点调研课题No.202209。

摘　　要：目的运用网络药理学及分子对接技术解析参芪扶正注射液(SFI)在非小细胞肺癌(NSCLC)与慢性阻塞性肺疾病(COPD)共病患者中的潜在分子机制。方法通过多个公共数据库筛选NSCLC-COPD的靶基因、SFI的有效活性成分及靶点。筛选出SFI抗NSCLC-COPD的主要活性成分和核心基因。同时,对关键基因进行了基因本体(GO)功能富集分析、京都基因和基因组数据库(KEGG)通路富集分析,以进一步揭示其生物学功能和参与的代谢途径。采用AutoDock Vina进行分子对接并计算结合能。结果共得到6664个NSCLC相关基因和9177个COPD相关基因。SFI的活性成分有41个,相应的靶基因有210个。SFI与NSCLC-COPD的交集基因共有50个。SFI在抗NSCLC-COPD的治疗中,其主要活性成分有槲皮素、7-O-甲基异鼠李素、山奈酚、木犀草素及7-甲氧基-2-甲基异黄酮等。这些关键成分共同构成了SFI的药效基础,发挥着重要的治疗作用。调控的关键基因有TP53、CCND1、CDK1等,主要富集于癌症通路、小细胞肺癌、爱泼斯坦-巴尔病毒感染、PI3K-Akt信号通路、人类T细胞白血病病毒1型感染信号通路等。分子对接结果提示SFI的主要活性成分靶点与NSCLC-COPD疾病核心靶点之间均存在较好的结合活性。结论FI通过多个靶点及途径有效治疗NSCLC合并COPD,为其在临床上的开发与应用提供了坚实的理论支撑。OBJECTIVE This study aims to analyze the potential molecular mechanism of ShenQi FuZheng Injection(SFI)in patients with non-small cell lung cancer(NSCLC)complicated with chronic obstructive pulmonary disease(COPD)using network pharmacology and molecular docking technology.METHODS Target genes of NSCLC-COPD and effective active ingredients and targets of SFI were screened through multiple public databases.The main active ingredients and core genes of SFI against NSCLC-COPD were screened out.At the same time,Gene Ontology(GO)function enrichment analysis and Kyoto Encyclopedia of Genes and Genomes(KEGG)pathway enrichment analysis were performed on key genes to further reveal their biological functions and involved metabolic pathways,aiming to understand the functions of these genes in organisms and the metabolic pathways they participate in.Molecular docking and binding energy calculation were performed using AutoDock Vina.RESULTS A total of 6664 NSCLC-related genes and 9177 COPD-related genes were obtained.There were 41 active ingredients of SFI with corresponding target genes of 210.A total of 50 intersecting genes were identified between SFI and NSCLC-COPD.In the treatment of NSCLC-COPD,the main active ingredients of SFI included quercetin,7-O-methylisorhamnetin,kaempferol,luteolin,and 7-methoxy-2-methylisoflavone.These key ingredients collectively constitute the pharmacologic basis of SFI and play important therapeutic roles.The key regulated genes included TP53,CCND1,CDK1,etc.,which were mainly enriched in cancer pathways,small cell lung cancer,Epstein-Barr virus infection,PI3K-Akt signaling pathway,human T-cell leukemia virus type 1 infection signaling pathway,etc.Molecular docking results suggested that there was good binding activity between the main active ingredient targets of SFI and the core targets of NSCLC-COPD.CONCLUSION SFI effectively treats NSCLC-COPD through multiple targets and pathways,providing solid theoretical support for its clinical development and application.

关 键 词：参芪扶正注射液 非小细胞肺癌 慢性阻塞性肺疾病 网络药理学 分子对接 

分 类 号：R94[医药卫生—药剂学]